EMA Stability requirement for variations

This presentation is compiled by “ Drug Regulations” a
non profit organization which provides free online
resource to the Pharmaceutical Professional.
Visit http://www.drugregulations.org for latest
information from the world of Pharmaceuticals.
4/16/2014 1

 This presentation is compiled from freely
available resources like the website of EMA
specifically “Guideline on stability testing for
applications for variations to a marketing
authorisation”
 “Drug Regulations” is a non profit organization
which provides free online resource to the
Pharmaceutical Professional.
 Visit http://www.drugregulations.org for latest
4/16/2014 2
Drug Regulations : Online
Resource for Latest Information

◦ Variations
 Require generation of stability data
 On the finished product or the active substance
 Continue the stability studies required, including commitment
batches, up to the approved shelf-life / retest period
 Inform authorities immediately if any problems with the stability
 e.g. if outside specification or potentially outside specification.
4/16/2014 3Drug Regulations : Online Resource for Latest Information

◦ Base the stability studies on the knowledge and experience acquired of the
active substances and finished products.
◦ The available information must be taken into account such as:
◦ a) For active substances:
 the stability profile including the results of stress testing, if applicable
(except herbals);
 the supportive data;
 the primary data of long term and accelerated testing.
◦ b) For finished products:
 the supportive data;
 the primary data of long term and accelerated testing.

◦ Assess whether the intended change has the
potential to impact the
 quality characteristics
 stability
 of the active substances and/or
 the finished products

 When stability data are required, the choice of test
conditions, refers to
◦ CHMP/ICH Guideline on Stability Testing of New Drug Substances
and Products,
◦ CHMP/QWP Guideline on Stability Testing of Existing Active
Substances and Related Finished Products,
◦ The CVMP/VICH Guideline on Stability Testing of New Veterinary
Drug Substances and Medicinal Products
◦ The CVMP/QWP Note for Guidance on Stability Testing of Existing
Active Substances and Related Finished Products, respectively.

 Type I variations
 If a variation to a marketing authorisation fulfils the conditions defined in the
Commission Regulation (EC) No 1234/2008 for Type IA variations, and if
stability data are required, the minimum set of data to be submitted with the
variation is defined in the Guidelines on the details of the various categories
of variations, on the operation of the procedures laid down in Chapters II, IIa,
III and IV of Commission Regulation (EC) No 1234/2008 of 24 November
2008 concerning the examination of variations to the terms of marketing
authorisations for medicinal products for human use and veterinary
medicinal products and on the documentation to be submitted pursuant to
those procedures.

 Type I variations
 A Type IB variation is the default category under the Commission Regulation (EC) No
1234/2008.
 The associated classification guideline provides examples of different types of Type IB
changes that have been included in the guideline with recommended documentation.
 Where a change may impact stability, the required stability data at the time of
submission are specified in the guideline.
 In other Type IB by default changes, which are not specifically described in the
classification guideline, the required stability data has to be decided on a case by case
basis.
 However, consideration should be given to specified requirements for any other similar
changes which have actually been included as examples in the guideline.

 Type II variations
 The Commission Regulation (EC) No 1234/2008 defines Type II variations as major variations which
may have a significant impact on the quality, safety or efficacy of medicinal products.
 Type II variations are defined in the Guidelines on the details of the various categories of variations, on
the operation of the procedures laid down in Chapters II, IIa, III and IV of the Commission Regulation
(EC) No 1234/2008 of 24 November 2008 concerning the examination of variations to the terms of
marketing authorisations for medicinal products for human use and veterinary medicinal products and
on the documentation to be submitted pursuant to those procedures.
 However, data to be submitted with these variations are not defined in the majority of cases.
 The following Type II variations refer to specific Type II variations as outlined in the Guidelines
mentioned above.
 The stability data outlined below should to be part of the documentation at submission of the
variation.

4/16/2014 10
Type II Variation . (B.I.a.1.b)
Change Requirement
• Change in the manufacturer of a starting material /
reagent / intermediate used in the manufacturing
process of the active substance
or
• change in the manufacturer (including where relevant
quality control testing sites) of the active substance,
where no
• Ph. Eur. certificate of suitability is part of the approved
dossier: Introduction of a manufacturer of active
substance supported by an ASMF
In case of an introduction of a manufacturer of the active
substance that is supported by an ASMF stability data
should be included in the applicants part of the ASMF.
In relation to stability data, of the active substance, the
recommendations given in the guideline on stability
testing of existing active substances and finished
products should be utilised.
If the quality characteristics/impurity profile of the active
substance are changed in a way that may impact the
stability of the finished product, additional stability data
on the finished product, in long term and accelerated*
conditions, six months data on at least two batches of at
least pilot scale batch size are recommended.

4/16/2014 11
Type II Variation . (B.I.a.1.c)
Change Requirement
• or
• change in the manufacturer (including where relevant
where no Ph. Eur. certificate of suitability is part of the
approved dossier:
• The proposed manufacturer uses a substantially
different route of synthesis or manufacturing
conditions, which may have a potential to change
important quality characteristics of the active
substance, such as qualitative and/or quantitative
impurity profile requiring qualification, or physico-
chemical properties impacting on bioavailability
In relation to stability data of the active substance, the
products should be utilised..
If the quality characteristics of the active substance are
changed in a way that may impact the stability of the
finished product, additional stability data on the finished
product, in long term and accelerated* testing

4/16/2014 12
Type II Variation . (B.I.a.1.g)
Change Requirement
• or
• Change in the manufacturer (including where relevant
where no Ph. Eur. certificate of suitability is part of the
approved dossier:
• Introduction of a new manufacturer of the active
substance that is not supported by an ASMF and
requires significant update to the relevant active
substance section of the dossier
In relation to stability data of the active substance, the
products should be utilised.

4/16/2014 13
Change Requirement
• Changes in the manufacturing process of the active
substance:
• Substantial changes to the manufacturing process of
the active substance which may have a significant
impact on the quality, safety or efficacy of the
medicinal product
In variations to the manufacturing process of the active
substance, the following approaches may be considered
as acceptable:
If the quality characteristics (e.g. physical characteristics,
impurity profile) of the active substance are changed in a
way that stability may be compromised, comparative
stability data are recommended in long term and
accelerated* testing conditions, on the active substance
before and after the change:
• for active substances known to be stable: three
months data on at least one batch of at least pilot
scale batch size (see Annex I for the definition of
stable active substance).

4/16/2014 14
Change Requirement
substance:
• Substantial changes to the manufacturing process of
the active substance which may have a significant
impact on the quality, safety or efficacy of the
medicinal product
• for active substances known to be unstable: six
months data on at least three batches of at least pilot
scale batch size.

4/16/2014 15
Type II Variation . (B.I.a.2.d)
Change Requirement
substance:
• The change relates to a herbal medicinal product and
there is a change to any of the following: geographical
source, manufacturing route or production
In variations to the manufacturing process of the active
substance, the following approaches may be considered
as acceptable:
impurity profile) of the active substance are changed in a
accelerated* term testing conditions, on the active
substance before and after the change:
• for active substances known to be stable: three
months data on at least one batch of at least pilot
scale batch size (see Annex I for the definition of
stable active substance).
• for active substances known to be unstable: six
months data on at least three batches of at least pilot
scale batch size.

4/16/2014 16
Type II Variation . (B.I.a.2.d)
Change Requirement
substance:
• The change relates to a herbal medicinal product and
there is a change to any of the following: geographical
source, manufacturing route or production

4/16/2014 17
Type II Variation . (B.I.c.1.b)
Change Requirement
• Change in immediate packaging of the active
substance:
• Qualitative and/or quantitative composition for sterile
and non-frozen biological/immunological active
substances
In case of a change to the immediate packaging of a
sterile active substance the following approach may be
considered as acceptable:
Comparative stability data are required using long term
and accelerated* testing conditions of six months in
duration on at least 2 batches of at least pilot scale of
the active substance.
(Note: According to the scope this guideline is not
applicable to biological/immunological active
substances).

4/16/2014 18
Type II Variation . (B.II.a.3.b.2)
Change Requirement
• Change in composition (excipients) of the finished
product:
• Qualitative or quantitative changes in one or more
excipients that may have a significant impact on the
safety, quality or efficacy of the medicinal product.
In case of a change in the composition of the finished
product, the following approaches may be considered as
acceptable:
For conventional dosage forms (e.g. conventional release
solid dosage form, solutions) and when the active
substance is known to be stable, comparative stability
data, 6 months in duration, long term and accelerated*
testing conditions on at least two batches of at least
pilot scale are recommended.
For critical dosage forms (e.g. modified release form) or
when the active substance is known to be unstable,
comparative stability data 6 months in duration, long
term and accelerated* stability testing conditions on at
least three primary batches are recommended. Two of
three batches should be at least pilot scale; the third
batch may be smaller.

4/16/2014 19
Type II Variation . (B.II.a.4.b)
Change Requirement
• Change in coating weight of oral dosage forms or
change in weight of capsule shells:
• Gastro-resistant, modified or prolonged release
pharmaceutical forms where the coating is a critical
factor for the release mechanism
In variations to the coating weight of oral dosage forms,
the following approach may be considered as acceptable:
• Comparative stability data, 6 months in duration, long

4/16/2014 20
Type II Variation . (B.II.a.5.)
Change Requirement
• Change in concentration of a single-dose, total use
parenteral product, where the amount of the active
substance per unit dose (i.e. the strength) remains the
same
In variations in concentration of single-dose, total use
parenteral product, the following approaches may be
• Comparative stability data, 6 months in duration, long

4/16/2014 21
Type II Variation . (B.II.b.1.c)
Change Requirement
• Replacement or addition of a manufacturing site for
part or all of the manufacturing process of the
finished product: Site where any manufacturing
operation(s) take place, except batch release, batch
control, and secondary packaging, for
biological/immunological medicinal products, or for
pharmaceutical forms manufactured by complex
manufacturing processes
In variations (replacement or addition) to a
manufacturing site for part or all of the manufacturing
process of the finished product, the following
approaches may be considered as acceptable:
• If the quality characteristics (e.g. physical
characteristics, impurity profile) of the finished
product are changed in a way that stability may be
compromised, comparative stability data are
recommended in long term and accelerated* testing
conditions, on the finished product before and after
the change:

4/16/2014 22
Type II Variation . (B.II.b.1.c)
Change Requirement
• Replacement or addition of a manufacturing site for
part or all of the manufacturing process of the
finished product: Site where any manufacturing
operation(s) take place, except batch release, batch
control, and secondary packaging, for
biological/immunological medicinal products, or for
comparative stability data, 6 months in duration, long
applicable to biological/immunological active substances
and related finished products).

4/16/2014 23
Type II Variation . (B.II.b.3.b)
Change Requirement
• Change in the manufacturing process of the finished
product, including an intermediate used in the
manufacture of the finished product:
• Substantial changes to a manufacturing process that
may have a significant impact on the quality, safety
and efficacy of the medicinal product
In variations to the manufacturing process of the
finished product, the following approaches may be
impurity profile) of the finished product are changed in a
accelerated* testing conditions, on the finished product
before and after the change:

4/16/2014 24
Type II Variation . (B.II.b.3.b)
Change Requirement
manufacture of the finished product:
• Substantial changes to a manufacturing process that
may have a significant impact on the quality, safety
and efficacy of the medicinal product

4/16/2014 25
Type II Variation . (B.II.b.3.d)
Change Requirement
manufacture of the finished product: Introduction of a
non-standard terminal sterilisation method
If the quality characteristics (e.g., impurity profile) of the
finished product are changed in a way that stability may
be compromised, comparative stability data are
conditions, on the finished product before and after the
change:
For conventional dosage forms (e.g. solutions) and when
the active substance is known to be stable, comparative
stability data, 6 months in duration, long term and
accelerated* testing conditions on at least two batches
of at least pilot scale are recommended.

4/16/2014 26
Change Requirement
manufacture of the finished product: Introduction of a
non-standard terminal sterilisation method
For critical dosage forms (e.g. suspensions or emulsions
for injection) or when the active substance is known to
be unstable, comparative stability data, 6 months in
duration, long term and accelerated* stability testing
conditions on at least three primary batches are
recommended. Two of three batches should be at least
pilot scale; the third batch may be smaller.

4/16/2014 27
Type II Variation . (B.II.b.3.e)
Change Requirement
manufacture of the finished product: introduction or
increase in the overage that is used for the active
substance
If the quality characteristics (e.g. content of active
substance) of the finished product are changed in a way
that stability may be compromised, comparative stability
data are recommended in long term and accelerated*
testing conditions, on the finished product before and
after the change:

4/16/2014 28
Change Requirement
• Change in the batch size (including batch size ranges)
of the finished product: The change relates to all other
In variations to the batch size of the finished product,
the following approaches may be considered as
acceptable:
If the quality characteristics (e.g. impurity profile) of the
change:
For conventional dosage forms manufactured by a
complex manufacturing process and when the active

4/16/2014 29
Type II Variation . (B.II.e.1.a.3)
Change Requirement
• Change in immediate packaging of the finished
product: Qualitative and quantitative composition:
Sterile medicinal products and
biological/immunological medicinal products
In case of a change to the immediate packaging of the
finished product the following approach may be
In the case of less protective packaging or when a risk of
interaction occurs for a sterile medicinal product,
comparative stability data are recommended using long
term and accelerated* testing conditions of six months
in duration on at least three primary batches of the
finished product. Two of three batches should be at least

4/16/2014 30
Type II Variation . (B.II.e.1a.4)
Change Requirement
product: Qualitative and quantitative composition: The
change relates to a less protective pack where there
are associated changes in storage conditions and/or
reduction in shelf life.
interaction occurs, mainly for semi-solid or liquid
dosage forms, comparative stability data are
recommended using long term and accelerated* testing
conditions of six months in duration on at least three
primary batches of the finished product. Two of three
batches should be at least pilot scale; the third batch
may be smaller.

4/16/2014 31
Type II Variation . (B.II.e.1.b.2)
Change Requirement
product:
• Change in type of container or addition of a new
container: Sterile medicinal products and
biological/immunological medicinal products
interaction occurs, mainly for semi-solid or liquid
dosage forms, comparative stability data are
recommended using long term and accelerated* testing
conditions of six months in duration on at least three
primary batches of the finished product. Two of three
batches should be at least pilot scale; the third batch
may be smaller.

4/16/2014 32
Type II Variation . (B.II.e.4.b)
Change Requirement
• Change in shape or dimensions of the container or
closure (immediate packaging):
• The change in shape or dimensions concerns a
fundamental part of the packaging material, which
may have a significant impact on the delivery, use,
safety or stability of the finished product
In variations to the immediate packaging of the finished
product, which may have a significant impact of the
stability of the finished product, the following approach
may be considered as acceptable:
change:
For conventional dosage forms manufactured by a
complex manufacturing process and when the active

4/16/2014 33
Type II Variation . (B.II.e.4.b)
Change Requirement
• Change in shape or dimensions of the container or
closure (immediate packaging):
• The change in shape or dimensions concerns a
fundamental part of the packaging material, which
may have a significant impact on the delivery, use,
safety or stability of the finished product

4/16/2014 34
Type II Variation . (B.II.e.5.c)
Change Requirement
• Change in pack size of the finished product:
• Change in fill weight/fill volume of sterile multidose
(or single-dose) parenteral medicinal product,
including biological/immunological medicinal
products
In case of such a change to the pack size of the finished
product the following approach may be considered as
acceptable:
change:
Comparative stability data are recommended using long
term and accelerated* testing conditions of six months
in duration on at least three primary batches of the
finished product. Two of three batches should be at least

 This presentation was compiled from freely
available resources like the website of EMA
specifically “Guideline on stability testing for
applications for variations to a marketing
authorisation”
 “Drug Regulations” is a non profit organization
which provides free online resource to the
Pharmaceutical Professional.
 Visit http://www.drugregulations.org for latest
4/16/2014 35
Drug Regulations : Online
Resource for Latest Information

EMA Stability requirement for variations

More Related Content

What's hot

Viewers also liked

Similar to EMA Stability requirement for variations

More from GMP EDUCATION : Not for Profit Organization

Recently uploaded

EMA Stability requirement for variations